NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.